Table 1.
Details of included studies and baseline characteristics of patients in warfarin group and DOACs group
| Authors | Year | Region | Study design | Study period | Sample size (n) | Age (years) | Males (%) | |||||
| Warfarin | DOAC | Warfarin | DOAC | Warfarin | DOAC | |||||||
| Bass et al | 2019 | United States | Retrospective | Sept 2012 – Oct 2018 | 769 | 180 | 70.9 | 69.4 | 63 | 65.6 | ||
| Daher et al | 2020 | France | Retrospective | Jan 2010 – Aug 2019 | 42 | 17 | 63 | 62.4 | 61 | 57 | ||
| Jaidka et al | 2018 | Canada | Retrospective | Not specified | 37 | 12 | 75 | 75 | 61.3 | 57 | ||
| Robinson et al | 2020 | United States | Retrospective | Oct 2013 – Mar 2019 | 236 | 121 | 72 | 77.7 | 58.2 | 58 | ||
| Jones et al | 2020 | United Kingdom | Observational | Not specified | 60 | 41 | 85 | 80.4 | 60.8 | 58.7 | ||
| Yunis et al | 2020 | United States | Retrospective | Jan 2014 – April 2019 | 200 | 64 | NR | NR | NR | NR | ||
| Ali et al | 2020 | United States | Retrospective | Jan 2012 – Jan 2019 | 60 | 32 | 58 | 59 | 81.6 | 81.3 | ||
| Iqbal et al | 2020 | United Kingdom | Retrospective | Dec 2012 – June 2018 | 62 | 22 | 89 | 91 | 62 | 62 | ||
| Hypertension (%) | Diabetes (%) | Smokers (%) | STEMI (%) | Assessment of Thrombus resolution | Type of DOAC used in the study | Follow-up duration | Primary end-point | |||||
| Warfarin | DOAC | Warfarin | DOAC | Warfarin | DOAC | Warfarin | DOAC | |||||
| NR | NR | NR | NR | NR | NR | 57.6 | 42.8 | NR | Not specified | Not specified | Incidence of thromboembolic stroke in patients receiving DOACs compared to warfarin. | |
| 40.5 | 59 | 21.4 | 12 | 59.5 | 59 | 74 | 88 | TTE |
Apixaban Rivaroxaban Dabigatran |
Not specified | Response to DOACs and VKAs | |
| 48.6 | 16.7 | 18.9 | 8.3 | 35 | 50 | 100 | 100 | TTE | Not specified | Not specified | Treatment and 6-month outcomes (embolic events, bleeding, and thrombus resolution). | |
| 75 | 71 | 39 | 29.8 | NR | NR | 62.7 | 54.5 | TTE |
Apixaban Rivaroxaban Dabigatran |
351 days | Risk of stroke or systemic embolization. | |
| 36.4 | 60.5 | 16.7 | 18.4 | 33.3 | 21 | 86.7 | 87.8 | TTE or CMR |
Apixaban Rivaroxaban Edoxaban |
2.2 year | Left ventricular thrombus resolution. | |
| NR | NR | NR | NR | NR | NR | NR | NR | Not specified | Not specified | 2 years | Survival and freedom from bleeding and from stroke and systemic embolism. | |
| NR | NR | 30 | 37.5 | 62 | 53 | NR | NR | TTE | Not specified | 1 year | Stroke or systemic embolism and thrombus resolution. | |
| 29 | 41 | 31 | 86 | 50 | 45 | 89 | 82 | CMR (initially) & TTE (follow-up) |
Apixaban Rivaroxaban Dabigatran |
3 years | Thromboembolic events and bleeding. | |
Abbreviations; CMR: Cardiac magnetic resonance; DOAC: Direct oral anticoagulant; NR: Not recorded; TTE: Transthoracic echocardiogram; STEMI: ST-segment elevation myocardial infarction